Journal article
Combined tamoxifen and luteinuzing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
JGM Klijn, RW Blamey, F Boccardo, T Tominaga, L Duchateau, R Sylvester, LVAM Beex, L Mauriac, JA Van Zijl, C Veyret, J Wildiers, J Jassem, M Piccart, J Burghouts, D Becqaert, C Seynaeve, F Mignolet, M Namer, JP Julien, J Garcia Conde Show all
Journal of Clinical Oncology | Published : 2001
Abstract
Purpose: The logic behind the application of luteinizing hormone-releasing hormone (LHRH) agonists in combination with tomoxifen in premenopausal women is that LHRH agonists on the one hand suppress the tamoxifen-induced stimulation of the pituitary-ovarian function and, on the other hand, seem as effective as surgical castration. This meta-analysis combines all randomized evidence to compare the combined treatment with LHRH agonist alone with respect to overall survival, progression-free survival, and objective response in premenopausal women with advanced breast cancer. Patients and Methods: Four clinical trials randomizing a total of 506 premenopausal women with advanced breast cancer to ..
View full abstract